Busca un médico

Moritz Binder, M.D., M.P.H.

  1. Hematologist
  2. Internist
Solicite una Consulta

Publicaciones

  1. Jevremovic D, Shi M, Horna P, Otteson GE, Timm MM, Bennett SA, Baughn LB, Greipp PT, Gonsalves WI, Kapoor P, Gertz MA, Binder M, Buadi FK, Dispenzieri A, Kourelis T, Muchtar E, Zhou J, Rajkumar SV, Kumar SK, Olteanu H. FDA IDE validation of multiple myeloma MRD test by flow cytometry. Am J Hematol 2024 Dec; 99 (12):2399-2401 Epub 2024 Sept 18
    View PubMed
  2. Charalampous C, Goel U, Kapoor P, Binder M, Buadi F, Dingli D, Dispenzieri A, Fonder A, Gertz M, Gonsalves W, Hayman S, Hobbs M, Hwa YL, Kourelis T, Lacy M, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar V, Kumar SK. Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies. Clin Lymphoma Myeloma Leuk. 2024 Oct; 24 (10):e329-e335 Epub 2024 June 01
    View PubMed
  3. Ben-Crentsil NA, Mohammed Ismail W, Balasis ME, Newman H, Quintana A, Binder M, Kruer T, Neupane S, Ferrall-Fairbanks MC, Fernandez J, Lasho TL, Finke CM, Ibrahim ML, McGraw KL, Wysota M, Aldrich AL, Ryder CB, Letson CT, Traina J, McLemore AF, Droin N, Shastri A, Yun S, Solary E, Sallman DA, Beg AA, Ma L, Gaspar-Maia A, Patnaik MM, Padron E. RNA shielding of P65 is required to potentiate oncogenic inflammation in TET2 mutated clonal hematopoiesis. Cancer Discov. 2024 Aug 27 [Epub ahead of print]
    View PubMed
  4. Claveau JS, Murray DL, Dispenzieri A, Kapoor P, Binder M, Buadi F, Dingli D, Fonder A, Gertz M, Gonsalves W, Hayman S, Hobbs M, Hwa YL, Kourelis T, Lacy M, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar V, Kumar SK. Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment. Leukemia. 2024 Aug; 38 (8):1863
    View PubMed
  5. Abdallah N, Murray D, Dispenzieri A, Kapoor P, Gertz MA, Lacy MQ, Hayman SR, Buadi FK, Gonsalves W, Muchtar E, Leung N, Dingli D, Kourelis T, Warsame R, Binder M, Kyle RA, Rajkumar SV, Kumar S. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia. 2024 Aug; 38 (8):1864
    View PubMed
  6. Jevremovic D, Shi M, Horna P, Otteson GE, Timm MM, Baughn LB, Greipp PT, Gonsalves WI, Kapoor P, Gertz MA, Binder M, Buadi FK, Zhou J, Dispenzieri A, Kourelis T, Muchtar E, Rajkumar SV, Kumar SK, Olteanu H. Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms. Blood Cancer J 2024 Jul 31; 14 (1):126 Epub 2024 July 31
    View PubMed
  7. Zanwar S, Gertz MA, Muchtar E, Buadi FK, Kourelis T, Gonsalves W, Go RS, Hayman S, Kapoor P, Binder M, Cook J, Dingli D, Leung N, Lin Y, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S, Dispenzieri A. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 2024 Jun; 38 (6):1423-1426 Epub 2024 Apr 09
    View PubMed
  8. Goel U, Charalampous C, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder A, Gertz MA, Gonsalves WI, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame RM, Kyle RA, Rajkumar SV, Kumar SK. Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide. Blood Cancer J. 2024 Mar 26; 14 (1):55
    View PubMed
  9. Abdallah NH, Lakshman A, Kumar SK, Cook J, Binder M, Kapoor P, Dispenzieri A, Gertz MA, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Lin Y, Kourelis T, Warsame R, Bergsagel L, Rajkumar SV. Mode of progression in smoldering multiple myeloma: a study of 406 patients. Blood Cancer J. 2024 Jan 17; 14 (1):9
    View PubMed
  10. Abdallah NH, Nagayama H, Takahashi N, Gonsalves W, Fonder A, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Hobbs M, Gertz MA, Binder M, Kapoor P, Warsame R, Hayman SR, Kourelis T, Hwa YL, Lin Y, Kyle RA, Rajkumar SV, Broski SM, Kumar SK. Muscle and fat composition in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2023 Dec 12; 13 (1):185
    View PubMed
  11. Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma. Blood Cancer J 2023 Dec 11; 13 (1):183
    View PubMed
  12. Yadav U, Kumar SK, Baughn LB, Dispenzieri A, Greipp P, Ketterling R, Jevremovic D, Buadi FK, Dingli D, Lacy MQ, Fonseca R, Bergsagel PL, Ailawadhi S, Roy V, Parrondo R, Sher T, Hayman SR, Kapoor P, Leung N, Cook J, Binder M, Muchtar E, Warsame R, Kourelis TV, Go RS, Lin Y, Seth A, Lester SC, Breen WG, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas. Blood. 2023 Nov 30; 142 (22):1871-1878
    View PubMed
  13. Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK, Dispenzieri A, Dingli D, Fonder A, Gertz MA, Gonsalves W, Hayman SR, Hwa Y, Hobbs M, Kourelis T, Lacy MQ, Leung N, Muchtar E, Warsame R, Jevremovic D, Kyle RA, Rajkumar SV, Kumar S. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. Am J Hematol. 2023 Oct; 98 (10):1540-1549 Epub 2023 July 08
    View PubMed
  14. Abdallah N, Dispenzieri A, Muchtar E, Buadi FK, Kapoor P, Lacy MQ, Hwa YL, Fonder A, Hobbs MA, Hayman SR, Leung N, Dingli D, Go RS, Lin Y, Gonsalves WI, Binder M, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, Gertz MA, Kumar SK. The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow up. Amyloid. 2023 Sep; 30 (3):261-267 Epub 2022 Dec 19
    View PubMed
  15. Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy. Blood Adv. 2023 Aug 22; 7 (16):4371-4380
    View PubMed
  16. Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Cook J, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy. Blood Adv. 2023 Aug 22; 7 (16):4371-4380
    View PubMed
  17. Schmidt WM, Perera ND, Buadi FK, Hayman SR, Kumar SK, Dispenzieri A, Dingli D, Cook J, Lacy MQ, Kapoor P, Leung N, Muchtar E, Warsame RM, Kourelis T, Binder M, Gonsalves WI, Hogan WJ, Gertz MA. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma. Blood Cancer J. 2023 Aug 18; 13 (1):126
    View PubMed
  18. Letson CT, Balasis ME, Newman H, Binder M, Vedder A, Kinose F, Ball M, Kruer T, Quintana A, Lasho TL, Finke CM, Almada LL, Grants JM, Zhang G, Fernandez-Zapico ME, Gaspar-Maia A, Lancet J, Komrokji R, Haura E, Sallman DA, Reuther GW, Karsan A, Rix U, Patnaik MM, Padron E. Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML. Clin Cancer Res. 2023 Aug 1; 29 (15):2919-2932
    View PubMed
  19. Visram A, Hayman SR, Dispenzieri A, Kapoor P, Lacy MQ, Gertz MA, Buadi FK, Dingli D, Warsame R, Kourelis T, Cook J, Binder M, Gonsalves W, Muchtar E, Leung N, Roy V, Rajkumar SV, Kumar S. A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL). Am J Hematol. 2023 Aug; 98 (8):1277-1285 Epub 2023 June 19
    View PubMed
  20. Sandoval L, Mohammed Ismail W, Mazzone A, Dumbrava M, Fernandez J, Munankarmy A, Lasho T, Binder M, Simon V, Kim KH, Chia N, Lee JH, Weroha SJ, Patnaik M, Gaspar-Maia A. Characterization and Optimization of Multiomic Single-Cell Epigenomic Profiling. Genes (Basel). 2023 Jun 10; 14 (6) Epub 2023 June 10
    View PubMed
  21. Lasho T, Finke C, Timm M, Tefferi A, Mangaonkar A, Olteanu H, Reichard K, Ketterling R, Gangat N, Xie Z, Fernandez J, Chia N, Gaspar-Maia A, Binder M, Patnaik MM. Single cell proteogenomic analysis of aberrant monocytosis in TET2 mutant premalignant and malignant hematopoiesis. Leukemia 2023 Jun; 37 (6):1384-1387 Epub 2023 Mar 25
    View PubMed
  22. Shreve JT, Hazim AZ, Bock AM, Pritchett JC, Maurer MJ, Shah MV, Binder M, Witzig TE, Wang Y, Nowakowski GS, Novak AJ, Young JR, Cerhan JR, Habermann TM, Ansell SM, Paludo J. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. Hematol Oncol. 2023 Jun; 41 Suppl 2:341-342
    View PubMed
  23. Abdallah NH, Smith AN, Geyer S, Binder M, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Hwa YL, Lin Y, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Conditional survival in multiple myeloma and impact of prognostic factors over time. Blood Cancer J. 2023 May 15; 13 (1):78
    View PubMed
  24. Soontrapa P, Klein CJ, Dyck PJB, Berini SE, McPhail ED, Binder M, Chompoopong P, Engelstad J, Shouman K. Amyloid-like IgM deposition neuropathy with multiple mononeuropathies and generalized neuropathy. Neuromuscul Disord. 2023 May; 33 (5):391-395 Epub 2023 Feb 24
    View PubMed
  25. Panakkal V, Lakshman A, Shi M, Olteanu H, Horna P, Timm MM, Otteson GE, Baughn LB, Greipp PT, Gonsalves WI, Kapoor P, Gertz MA, Binder M, Buadi FK, Dispenzieri A, Rajkumar SV, Kumar SK, Jevremovic D. Utility of flow cytometry screening before MRD testing in multiple myeloma. Blood Cancer J 2023 Apr 20; 13 (1):55
    View PubMed
  26. Wang YH, Yao CY, Lin CC, Gurashi K, Amaral FMR, Bossenbroek H, Jerez A, Somervaille TCP, Binder M, Patnaik MM, Hou HA, Chou WC, Batta K, Wiseman DH, Tien HF. A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia. Br J Haematol. 2023 Apr; 201 (2):302-307 Epub 2023 Feb 06
    View PubMed
  27. Goldman-Mazur S, Visram A, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Dingli D, Kourelis T, Gonsalves W, Warsame R, Muchtar E, Leung N, Binder M, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar SK. Outcomes after biochemical or clinical progression in patients with multiple myeloma. Blood Adv. 2023 Mar 28; 7 (6):909-917
    View PubMed
  28. Charalampous C, Goel U, Kapoor P, Binder M, Buadi FK, Dingli D, Dispenzieri A, Fonder AL, Gertz MA, Gonsalves W, Hayman SR, Hobbs MA, Hwa YL, Kourelis T, Lacy MQ, Leung N, Lin Y, Warsame R, Kyle RA, Rajkumar SV, Kumar S. Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival. Am J Hematol. 2023 Mar; 98 (3):413-420 Epub 2023 Jan 01
    View PubMed
  29. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan A, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. Am J Hematol. 2023 Jan; 98 (1):49-55 Epub 2022 Oct 24
    View PubMed
  30. Claveau JS, Murray DL, Dispenzieri A, Kapoor P, Binder M, Buadi F, Dingli D, Fonder A, Gertz M, Gonsalves W. Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment. Leukemia. 2023 Jan; 37(1):1-4. Epub 2022 Dec 08.
    View PubMed
  31. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan AA, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance. Blood. 2022 Nov 3; 140 (18):1997-2000
    View PubMed
  32. Ebraheem M, Kumar SK, Dispenzieri A, Jevremovic D, Buadi FK, Dingli D, Cook J, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Binder M, Lin Y, Go RS, Siddiqui MA, Kyle RA, Rajkumar SV, Gonsalves WI, Gertz MA. Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy. Transplant Cell Ther. 2022 Nov; 28 (11):760.e1-760.e5 Epub 2022 Aug 05
    View PubMed
  33. Ebraheem M, Kumar SK, Dispenzieri A, Jevremovic D, Buadi FK, Dingli D, Cook J, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Russell S, Binder M, Lin Y, Go RS, Siddiqui MA, Kyle RA, Rajkumar SV, Gonsalves WI, Gertz MA. Deepening responses after upfront autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in the era of novel agent induction therapy. Transplantation and Cellular Therapy. 2022 Nov; 28 (11):Pages 760.e1-5
  34. Charalampous C, Goel U, Broski SM, Dingli D, Kapoor P, Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Buadi F, Hwa L, Leung N, Lin Y, Gonsalves WI, Kourelis TV, Warsame R, Fonder A, Hobbs M, Binder M, Kyle RA, Rajkumar SV, Kumar SK. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. Blood Adv. 2022 May 10; 6 (9):2763-2772
    View PubMed
  35. Abdallah N, Murray D, Dispenzieri A, Kapoor P, Gertz MA, Lacy MQ, Hayman SR, Buadi FK, Gonsalves W, Muchtar E, Leung N, Dingli D, Kourelis T, Warsame R, Binder M, Kyle RA, Rajkumar SV, Kumar S. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia. 2022 May; 36 (5):1449
    View PubMed
  36. Abdallah N, Murray D, Dispenzieri A, Kapoor P, Gertz MA, Lacy MQ, Hayman SR, Buadi FK, Gonsalves W, Muchtar E, Leung N, Dingli D, Kourelis T, Warsame R, Binder M, Kyle RA, Rajkumar SV, Kumar S. Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia 2022 May; 36 (5):1426-1428 Epub 2022 Jan 29
    View PubMed
  37. Abdallah NH, Habermann T, Buadi FK, Gertz MA, Lacy MQ, Rajkumar SV, Dingli D, Go RS, Hayman SR, Kumar SK, Kourelis T, Warsame R, Kapoor P, Muchtar E, Hwa YL, Fonder AL, Hobbs MA, Lin Y, Leung N, Binder M, Siddiqui MA, Kyle RA, Witzig TE, Dispenzieri A. Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. Am J Hematol. 2022 Apr; 97(4):401-410. Epub 2022 Jan 19.
    View PubMed
  38. Binder M, Carr RM, Lasho TL, Finke CM, Mangaonkar AA, Pin CL, Berger KR, Mazzone A, Potluri S, Ordog T, Robertson KD, Marks DL, Fernandez-Zapico ME, Gaspar-Maia A, Patnaik MM. Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia. Nat Commun. 2022 Mar 17; 13 (1):1434
    View PubMed
  39. Kaddoura M, Binder M, Dingli D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Hwa L, Fonder A, Hobbs M, Hayman S, Leung N, Go RS, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Rajkumar V, Kumar S. Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. Am J Hematol. 2022 Mar 01; 97(3):267-273. Epub 2022 Jan 03.
    View PubMed
  40. Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, Lacy MQ, Gertz MA, Hayman SR, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Gonsalves WI, Russell S, Lin Y, Siddiqui M, Kyle RA, Dispenzieri A, Kumar SK. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022 Mar; 36(3):801-808. Epub 2021 Oct 26.
    View PubMed
  41. You X, Liu F, Binder M, Vedder A, Lasho T, Wen Z, Gao X, Flietner E, Rajagopalan A, Zhou Y, Finke C, Mangaonkar A, Liao R, Kong G, Ranheim EA, Droin N, Hunter AM, Nikolaev S, Balasis M, Abdel-Wahab O, Levine RL, Will B, Nadiminti KVG, Yang D, Geissler K, Solary E, Xu W, Padron E, Patnaik MM, Zhang J. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation. Blood. 2022 Feb 17; 139 (7):1066-1079
    View PubMed
  42. Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder AL, Hobbs MA, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui MA, Kyle RA, Bergsagel PL, Fonseca R, Ketterling RP, Kumar SK. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022 Jan 31; 12 (1):21
    View PubMed
  43. Muchtar E, Drake MT, Leung N, Dispenzieri A, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell S, Go RS, Binder M, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome. Front Endocrinol (Lausanne). 2022; 13:891712 Epub 2022 June 21
    View PubMed
  44. Kuenzlen L, Nasim S, Neerven SV, Binder M, Wellenbrock S, Kuhn S, Spennato S, Rieger UM, Bozkurt A. Multimodal evaluation of donor site morbidity in transgender individuals after phalloplasty with a free radial forearm flap: a case-control study. J Plast Reconstr Aesthet Surg. 2022 Jan; 75 (1):25-32 Epub 2021 June 17
    View PubMed
  45. Sharma N, Smadbeck JB, Abdallah N, Zepeda-Mendoza C, Binder M, Pearce KE, Asmann YW, Peterson JF, Ketterling RP, Greipp PT, Bergsagel PL, Rajkumar SV, Kumar SK, Baughn LB. The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma. Clin Cancer Res. 2021 Oct 1; 27 (19):5430-5439
    View PubMed
  46. Carr RM, Vorobyev D, Lasho T, Marks DL, Tolosa EJ, Vedder A, Almada LL, Yurcheko A, Padioleau I, Alver B, Coltro G, Binder M, Safgren SL, Horn I, You X, Solary E, Balasis ME, Berger K, Hiebert J, Witzig T, Buradkar A, Graf T, Valent P, Mangaonkar AA, Robertson KD, Howard MT, Kaufmann SH, Pin C, Fernandez-Zapico ME, Geissler K, Droin N, Padron E, Zhang J, Nikolaev S, Patnaik MM. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nat Commun. 2021 May 18; 12 (1):2901
    View PubMed
  47. Li M, Binder M, Lasho T, Ferrer A, Gangat N, Al-Kali A, Mangaonkar A, Elliott M, Litzow M, Hogan W, Pardanani A, Wolanskyj-Spinner A, Howard M, King RL, Shah M, Alkhateeb H, Begna K, Tefferi A, Finke C, Oliveira J, Ketterling R, Olteanu H, Patnaik MM. Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. Blood Adv. 2021 Apr 27; 5 (8):2272-2278
    View PubMed
  48. Buradkar A, Bezerra E, Coltro G, Lasho TL, Finke CM, Gangat N, Carr RM, Binder M, Mangaonkar AA, Ketterling R, Khan S, Rodriguez V, Tefferi A, Patnaik MM. Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. Leukemia. 2021 Feb; 35 (2):644-649 Epub 2020 June 08
    View PubMed
  49. Wudhikarn K, Loghavi S, Mangaonkar AA, Al-Kali A, Binder M, Carr R, Reichard K, Finke C, Howard M, Gangat N, Tefferi A, Komrokji R, Ali N, Lasho T, Ketterling R, Padron E, Patnaik MM. SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Adv 2020 Nov 24; 4 (22):5716-5721
    View PubMed
  50. Mangaonkar AA, Reichard KK, Binder M, Coltro G, Lasho TL, Carr RM, Chiu A, Negron V, Hefazi M, Anagnostou T, Timm MM, Hiebert JW, Villasboas JC, Gonsalves WI, Gangat N, Shah M, Alkhateeb HB, Al-Kali A, Elliott MA, Begna KH, Wolanskyj-Spinner AP, Litzow MR, Hogan WJ, Ansell SM, Pardanani A, Tefferi A, Patnaik MM. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. Blood Adv. 2020 Nov 10; 4(21):5425-5430.
    View PubMed
  51. Taylor J, Mi X, North K, Binder M, Penson A, Lasho T, Knorr K, Haddadin M, Liu B, Pangallo J, Benbarche S, Wiseman D, Tefferi A, Halene S, Liang Y, Patnaik MM, Bradley RK, Abdel-Wahab O. Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms. Blood. 2020 Sep 24; 136 (13):1477-1486
    View PubMed
  52. DiFilippo EC, Coltro G, Carr RM, Mangaonkar AA, Binder M, Khan SP, Rodriguez V, Gangat N, Wolanskyj A, Pruthi RK, Chen D, He R, Viswanatha DS, Lasho T, Finke C, Tefferi A, Pardanani A, Patnaik MM. Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. Leukemia 2020 Sep; 34 (9):2519-2524 Epub 2020 Feb 14
    View PubMed
  53. Patnaik MM, Sallman DA, Mangaonkar AA, Heuer R, Hirvela J, Zblewski D, Al-Kali A, Binder M, Balasis ME, Newman H, Letson C, Kruer TL, Gangat N, Komrokji RS, Tefferi A, Lo A, Shih T, Durrant C, List AF, Padron E. Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood. 2020 Aug 13; 136 (7):909-913
    View PubMed
  54. Mellors PW, Binder M, Ketterling RP, Greipp PT, Baughn LB, Peterson JF, Jevremovic D, Pearce KE, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Lust JA, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Adv. 2020 May 26; 4 (10):2236-2244
    View PubMed
  55. Coltro G, Mangaonkar AA, Lasho TL, Finke CM, Pophali P, Carr R, Gangat N, Binder M, Pardanani A, Fernandez-Zapico M, Robertson KD, Bosi A, Droin N, Vannucchi AM, Tefferi A, Hunter A, Padron E, Solary E, Patnaik MM. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. Leukemia. 2020 May; 34 (5):1407-1421 Epub 2019 Dec 13
    View PubMed
  56. Sidana S, Milani P, Binder M, Basset M, Tandon N, Foli A, Dispenzieri A, Gertz MA, Hayman SR, Buadi FK, Lacy MQ, Kapoor P, Leung N, Rajkumar SV, Merlini G, Palladini G, Kumar SK. A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. Blood Cancer J. 2020 Apr 14; 10 (4):41
    View PubMed
  57. Mangaonkar AA, Swoboda DM, Coltro G, Lasho TL, Novotny PJ, Pophali P, Carr RM, Binder M, Finke CM, Gangat N, Al-Kali A, Begna KH, Reichard KK, Ketterling RP, Al Ali NH, Vafaii P, Zhang L, Padron E, Talati C, Patnaik MM. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia 2020 Feb; 34 (2):656-661 Epub 2019 Sept 11
    View PubMed
  58. Mitev A, Christ L, Feldmann D, Binder M, Moller K, Kanne AM, Hugle T, Villiger PM, Voll RE, Finzel S, Kollert F. Inflammatory stays inflammatory: a subgroup of systemic sclerosis characterized by high morbidity and inflammatory resistance to cyclophosphamide. Arthritis Res Ther. 2019 Dec 2; 21 (1):262 Epub 2019 Dec 02
    View PubMed
  59. Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Rajkumar SV, Kumar SK. Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. Leuk Lymphoma. 2019 Dec; 60 (12):2960-2967 Epub 2019 May 16
    View PubMed
  60. Coston T, Pophali P, Vallapureddy R, Lasho TL, Finke CM, Ketterling RP, Carr R, Binder M, Mangaonkar AA, Gangat N, Al-Kali A, Litzow M, Zblewski D, Pardanani A, Tefferi A, Patnaik MM. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. Am J Hematol. 2019 Jul; 94 (7):767-779 Epub 2019 May 03
    View PubMed
  61. Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK. Substratification of patients with newly diagnosed standard-risk multiple myeloma. Br J Haematol. 2019 Apr; 185 (2):254-260 Epub 2019 Feb 15
    View PubMed
  62. Binder M, Rajkumar SV, Lacy MQ, Gertz MA, Buadi FK, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Hayman SR, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Kumar SK. Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. Am J Hematol. 2019 Mar; 94 (3):306-311 Epub 2018 Dec 13
    View PubMed
  63. Freis A, Dietrich JE, Binder M, Holschbach V, Strowitzki T, Germeyer A. Relative Morphokinetics Assessed by Time-Lapse Imaging Are Altered in Embryos From Patients With Endometriosis. Reprod Sci. 2018 Aug; 25 (8):1279-1285 Epub 2017 Nov 15
    View PubMed
  64. Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Vincent Rajkumar S, Kumar SK. Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. Am J Hematol. 2018 Jul; 93 (7):889-894
    View PubMed
  65. Ramos GP, Binder M, Hampel P, Braga Neto MB, Sunjaya D, Al Bawardy B, Abu Dayyeh BK, Buttar NS, Bruining DH, Coelho-Prabhu N, Prabhu-Coelho N, Larson MV, Wong Kee Song LM, Rajan E. Outcomes of endoscopic intervention for overt GI bleeding in severe thrombocytopenia. Gastrointest Endosc. 2018 Jul; 88 (1):55-61 Epub 2018 Feb 02
    View PubMed
  66. Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018 Jun 12; 8(6):59.
    View PubMed
  67. Cotter TG, Binder M, Loftus EV Jr, Abboud R, McNally MA, Smyrk TC, Tremaine WJ, Sandborn WJ, Pardi DS. Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study. Gut. 2018 Mar; 67 (3):441-446 Epub 2016 Dec 13
    View PubMed
  68. Binder M, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer J. 2017 Sep 1; 7 (9):e600 Epub 2017 Sept 01
    View PubMed
  69. Binder M, O'Byrne MM, Maurer MJ, Ansell S, Feldman AL, Cerhan J, Novak A, Porrata LF, Markovic S, Link BK, Witzig TE. Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. Am J Hematol. 2017 Aug; 92 (8):752-758 Epub 2017 June 01
    View PubMed
  70. Cotter TG, Binder M, Harper EP, Smyrk TC, Pardi DS. Optimization of a Scoring System to Predict Microscopic Colitis in a Cohort of Patients With Chronic Diarrhea. J Clin Gastroenterol. 2017 Mar; 51 (3):228-234
    View PubMed
  71. Podboy A, Sunjaya D, Smyrk TC, Murray JA, Binder M, Katzka DA, Alexander JA, Halland M. Oesophageal lichen planus: the efficacy of topical steroid-based therapies. Aliment Pharmacol Ther. 2017 Jan; 45 (2):310-318 Epub 2016 Nov 17
    View PubMed
  72. Binder M, Alkhateeb HB, Go RS. 61-Year-Old Man With Right Knee Pain and Chronic Anemia. Mayo Clin Proc. 2016 Nov; 91 (11):1640-1644 Epub 2016 Aug 04
    View PubMed
  73. Binder M, Zhang BY, Hillman DW, Kohli R, Kohli T, Lee A, Kohli M. Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. Int J Mol Sci. 2016 Jul 9; 17 (7) Epub 2016 July 09
    View PubMed
  74. Kekre N, Mak KS, Stopsack KH, Binder M, Ishii K, Branvall E, Cutler CS. Impact of HLA-Mismatch in Unrelated Donor Hematopoietic Stem Cell Transplantation: A Meta-Analysis. Am J Hematol. 2016 Jun; 91 (6):551-5 Epub 2016 Apr 13
    View PubMed
  75. Binder M, Rajkumar SV, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA, Kumar SK. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma. Blood Cancer J. 2016 Mar 11; 6:e401
    View PubMed
  76. Binder M, Shui IM, Wilson KM, Penney KL, Mucci LA, Kibel AS, PRACTICAL/ELLIPSE Consortium. Calcium intake, polymorphisms of the calcium-sensing receptor, and recurrent/aggressive prostate cancer. Cancer Causes Control. 2015 Dec; 26 (12):1751-9 Epub 2015 Sept 25
    View PubMed
  77. Binder M, Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Buadi FK, Dingli D, Hayman SR, Lust JA, Kapoor P, Lin Y, Go RS, Hwa YL, Kyle RA, Kumar SK. Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. Am J Hematol. 2015 Oct; 90: (10)888-91.
    View PubMed
  78. Kollert F, Christoph S, Probst C, Budweiser S, Bannert B, Binder M, Sehnert B, Voll RE, Warnatz K, Zissel G, Walker UA, Prasse A, Saalbach A. Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis. Arthritis Care Res (Hoboken). 2013 Feb; 65 (2):281-7
    View PubMed
  79. Binder M, Christoph S, Sehnert B, Uhl M, Peter HH, Voll RE, Warnatz K, Kollert F. Elevated serum osteopontin levels in idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol. 2012 Sep-Oct; 30 (5):772-5 Epub 2012 Oct 17
    View PubMed
  80. Kollert F, Binder M, Probst C, Uhl M, Zirlik A, Kayser G, Voll RE, Peter HH, Zissel G, Prasse A, Warnatz K. CCL18 -- potential biomarker of fibroinflammatory activity in chronic periaortitis. J Rheumatol. 2012 Jul; 39 (7):1407-12 Epub 2012 May 15
    View PubMed
PST-20517312